Our lead compounds, 2800Z and 40569Z, specifically inhibited the deacetylation activity of SIRT7, blocked proliferation, enhanced chemosensitivity of sorafenib, and reduced tumor burden both in vitro and in vivo. Here, SIRT7 is linked to neoplasm.